Global Epilepsy Therapeutic Market Size, Status, Research and Forecast 2019-2025

Published On: Jul 2019

Format: PDF

Publisher: QY Research

Pages: 102

Report ID: 4083

Epilepsy is characterized by recurrent seizures caused by the improper balance between inhibitory and excitatory signals in the brain. The symptoms of epilepsy, caused by brain malformations and tumors, birth trauma, and high-risk pregnancies, can be benign or life-threatening. A majority of epilepsy cases have an unknown etiology.
In terms of geography, the Americas led the global epilepsy therapeutic market and is likely to hold close to 50% of the revenue market shares. The growth of this market in the region is due to the high prevalence of the disorder and the availability of treatment options in the region, especially in the developed markets such as the US and Canada.
In 2018, the global Epilepsy Therapeutic market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Epilepsy Therapeutic status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Epilepsy Therapeutic development in United States, Europe and China.

The key players covered in this study
Abbott Laboratories
GlaxoSmithKline Plc
UCB
Cephalon
Johnson & Johnson
Pfizer
Novartis AG
Abbvie
Janssen Pharmaceuticals
Sunovion Pharmaceuticals
Valeant Pharmaceuticals International
Sanofi S.A
Shire
Eisai
F. Hoffmann-La Roche

Market segment by Type, the product can be split into
First Generation
Second Generation

Market segment by Application, split into
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Epilepsy Therapeutic status, future forecast, growth opportunity, key market and key players.
To present the Epilepsy Therapeutic development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Epilepsy Therapeutic are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Epilepsy Therapeutic Market Size Growth Rate by Type (2014-2025)
1.4.2 First Generation
1.4.3 Second Generation
1.5 Market by Application
1.5.1 Global Epilepsy Therapeutic Market Share by Application (2014-2025)
1.5.2 Hospital Pharmacies
1.5.3 Retail Pharmacies
1.5.4 Online Pharmacies
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Epilepsy Therapeutic Market Size
2.2 Epilepsy Therapeutic Growth Trends by Regions
2.2.1 Epilepsy Therapeutic Market Size by Regions (2014-2025)
2.2.2 Epilepsy Therapeutic Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 Epilepsy Therapeutic Market Size by Manufacturers
3.1.1 Global Epilepsy Therapeutic Revenue by Manufacturers (2014-2019)
3.1.2 Global Epilepsy Therapeutic Revenue Market Share by Manufacturers (2014-2019)
3.1.3 Global Epilepsy Therapeutic Market Concentration Ratio (CR5 and HHI)
3.2 Epilepsy Therapeutic Key Players Head office and Area Served
3.3 Key Players Epilepsy Therapeutic Product/Solution/Service
3.4 Date of Enter into Epilepsy Therapeutic Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Epilepsy Therapeutic Market Size by Type (2014-2019)
4.2 Global Epilepsy Therapeutic Market Size by Application (2014-2019)

5 United States
5.1 United States Epilepsy Therapeutic Market Size (2014-2019)
5.2 Epilepsy Therapeutic Key Players in United States
5.3 United States Epilepsy Therapeutic Market Size by Type
5.4 United States Epilepsy Therapeutic Market Size by Application

6 Europe
6.1 Europe Epilepsy Therapeutic Market Size (2014-2019)
6.2 Epilepsy Therapeutic Key Players in Europe
6.3 Europe Epilepsy Therapeutic Market Size by Type
6.4 Europe Epilepsy Therapeutic Market Size by Application

7 China
7.1 China Epilepsy Therapeutic Market Size (2014-2019)
7.2 Epilepsy Therapeutic Key Players in China
7.3 China Epilepsy Therapeutic Market Size by Type
7.4 China Epilepsy Therapeutic Market Size by Application

8 Japan
8.1 Japan Epilepsy Therapeutic Market Size (2014-2019)
8.2 Epilepsy Therapeutic Key Players in Japan
8.3 Japan Epilepsy Therapeutic Market Size by Type
8.4 Japan Epilepsy Therapeutic Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Epilepsy Therapeutic Market Size (2014-2019)
9.2 Epilepsy Therapeutic Key Players in Southeast Asia
9.3 Southeast Asia Epilepsy Therapeutic Market Size by Type
9.4 Southeast Asia Epilepsy Therapeutic Market Size by Application

10 India
10.1 India Epilepsy Therapeutic Market Size (2014-2019)
10.2 Epilepsy Therapeutic Key Players in India
10.3 India Epilepsy Therapeutic Market Size by Type
10.4 India Epilepsy Therapeutic Market Size by Application

11 Central & South America
11.1 Central & South America Epilepsy Therapeutic Market Size (2014-2019)
11.2 Epilepsy Therapeutic Key Players in Central & South America
11.3 Central & South America Epilepsy Therapeutic Market Size by Type
11.4 Central & South America Epilepsy Therapeutic Market Size by Application

12 International Players Profiles
12.1 Abbott Laboratories
12.1.1 Abbott Laboratories Company Details
12.1.2 Company Description and Business Overview
12.1.3 Epilepsy Therapeutic Introduction
12.1.4 Abbott Laboratories Revenue in Epilepsy Therapeutic Business (2014-2019)
12.1.5 Abbott Laboratories Recent Development
12.2 GlaxoSmithKline Plc
12.2.1 GlaxoSmithKline Plc Company Details
12.2.2 Company Description and Business Overview
12.2.3 Epilepsy Therapeutic Introduction
12.2.4 GlaxoSmithKline Plc Revenue in Epilepsy Therapeutic Business (2014-2019)
12.2.5 GlaxoSmithKline Plc Recent Development
12.3 UCB
12.3.1 UCB Company Details
12.3.2 Company Description and Business Overview
12.3.3 Epilepsy Therapeutic Introduction
12.3.4 UCB Revenue in Epilepsy Therapeutic Business (2014-2019)
12.3.5 UCB Recent Development
12.4 Cephalon
12.4.1 Cephalon Company Details
12.4.2 Company Description and Business Overview
12.4.3 Epilepsy Therapeutic Introduction
12.4.4 Cephalon Revenue in Epilepsy Therapeutic Business (2014-2019)
12.4.5 Cephalon Recent Development
12.5 Johnson & Johnson
12.5.1 Johnson & Johnson Company Details
12.5.2 Company Description and Business Overview
12.5.3 Epilepsy Therapeutic Introduction
12.5.4 Johnson & Johnson Revenue in Epilepsy Therapeutic Business (2014-2019)
12.5.5 Johnson & Johnson Recent Development
12.6 Pfizer
12.6.1 Pfizer Company Details
12.6.2 Company Description and Business Overview
12.6.3 Epilepsy Therapeutic Introduction
12.6.4 Pfizer Revenue in Epilepsy Therapeutic Business (2014-2019)
12.6.5 Pfizer Recent Development
12.7 Novartis AG
12.7.1 Novartis AG Company Details
12.7.2 Company Description and Business Overview
12.7.3 Epilepsy Therapeutic Introduction
12.7.4 Novartis AG Revenue in Epilepsy Therapeutic Business (2014-2019)
12.7.5 Novartis AG Recent Development
12.8 Abbvie
12.8.1 Abbvie Company Details
12.8.2 Company Description and Business Overview
12.8.3 Epilepsy Therapeutic Introduction
12.8.4 Abbvie Revenue in Epilepsy Therapeutic Business (2014-2019)
12.8.5 Abbvie Recent Development
12.9 Janssen Pharmaceuticals
12.9.1 Janssen Pharmaceuticals Company Details
12.9.2 Company Description and Business Overview
12.9.3 Epilepsy Therapeutic Introduction
12.9.4 Janssen Pharmaceuticals Revenue in Epilepsy Therapeutic Business (2014-2019)
12.9.5 Janssen Pharmaceuticals Recent Development
12.10 Sunovion Pharmaceuticals
12.10.1 Sunovion Pharmaceuticals Company Details
12.10.2 Company Description and Business Overview
12.10.3 Epilepsy Therapeutic Introduction
12.10.4 Sunovion Pharmaceuticals Revenue in Epilepsy Therapeutic Business (2014-2019)
12.10.5 Sunovion Pharmaceuticals Recent Development
12.11 Valeant Pharmaceuticals International
12.12 Sanofi S.A
12.13 Shire
12.14 Eisai
12.15 F. Hoffmann-La Roche

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details